Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study

Currently, there are limited treatment options for patients who developed resistance to osimertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor. Resistance to EGFR inhibitors is frequently associated with enhanced vascular endothelial growth factor (VEGF) levels. This multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xue, Xia, Yang, Xu, Liyan, Liang, Li, Zhuo, Minglei, Wu, Meina, An, Tongtong, Wang, Ziping, Wang, Yuyan, Li, Jianjie, Zhong, Jia, Chen, Hanxiao, Jia, Bo, Wang, Jingjing, Zhao, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131525/
https://www.ncbi.nlm.nih.gov/pubmed/34026823
http://dx.doi.org/10.3389/fmolb.2021.639892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131525/
https://www.ncbi.nlm.nih.gov/pubmed/34026823
http://dx.doi.org/10.3389/fmolb.2021.639892

Ejemplares similares